INTRODUCTION
============

Colitis-associated carcinogenesis ranks the third most frequently diagnosed cancers worldwide[@b1-jcp-21-271] and the major cause of death in women with age above 65 years old in Korea and Japan.[@b2-jcp-21-271],[@b3-jcp-21-271] The gender difference in the prevalence of colorectal cancer is the universal phenomenon, not restricted to specific area or races.[@b1-jcp-21-271] The prevalence of advanced colorectal neoplasms is higher among men than women; cross-sectional analyses estimated that men reach an equivalent prevalence at a much younger age than women.[@b4-jcp-21-271] The tumor location also differs according to gender; women are more frequently diagnosed of the cancer in the right-sided colon.[@b5-jcp-21-271] The tumors in the right-sided colon are associated with microsatellite instability (MSI)-positive and/or CpG island methylator phenotype (CIMP)-positive tumors, known as the more aggressive type than those with chromosomal instability, which may explain the short-period progression in women.[@b5-jcp-21-271] Therefore, it is recommended for scientific researches to consider sex-associated differences in colitis-associated carcinogenesis.

Colitis-associated cancer is a type of cancer that occurred as a complication of long-term chronic bowel inflammation such as the Crohn's disease and ulcerative colitis.[@b6-jcp-21-271] Chronic inflammatory environments drive cells to malignant transformation to promote tumorigenesis by oxidative stress and the pro-inflammatory factors such as interleukin (IL)-6, IL-1β, TNF-α and myeloperoxidase (MPO).[@b7-jcp-21-271]--[@b10-jcp-21-271] However, these factors are no information regarding sex-associated differences in colitis-associated cancer.

Experimental animal models can imitate many characteristics of colon cancer, and they are important in studying the underlying mechanisms of the initiation and progression of colon cancers.[@b11-jcp-21-271] For the mimic of colitis-associated colon tumorigenesis, mice were injected with the carcinogen azoxymethane (AOM) and subsequently treated with the pro-inflammatory agent dextran sulfate sodium (DSS) to develop numerous tumors.[@b12-jcp-21-271]--[@b14-jcp-21-271] The treatment of AOM prevents the resolution of DSS-induced inflammation and promotes dysplasia and hyperplasia.[@b15-jcp-21-271] Tumor growth in AOM/DSS model is directly influenced by the associated inflammatory process. In this model, the development of adequate tumor is confirmed in several mouse strains within 20 weeks.[@b13-jcp-21-271],[@b16-jcp-21-271]

Hence we investigated the effect of sex-associated differences on AOM/DSS-induced colitis-associated carcinogenesis model.

MATERIALS AND METHODS
=====================

1. Animals
----------

Four-week-old male and female ICR mice (Orient Co., Ltd., Seoul, Korea) were used for the experiments. Every mouse was housed in cages maintained at 23°C with a 12/12-hour light/dark cycle under specific pathogen-free conditions. All experimental procedures were approved by the Institutional Animal Care and Use Committee of Seoul National University Bundang Hospital (BA1310-139/091-01). The procedures were in accordance with the ARRIVE (Animals in Research: Reporting In Vivo Experiments) statement.

2. Experimental design
----------------------

Experimental groups were consisted of the following 12 groups: group 1--4 sacrificed at the fourth week; group 5--8 sacrificed at the 10th week; and group 9--12 sacrificed at the 16th week: group 1, 5, 9 (male control, n = 5, respectively); group 2, 6, 10 (male treated with AOM and DSS, n = 10, respectively); group 3, 7, 11 (female control, n = 5, respectively); group 4, 8, 12 (female treated with AOM and DSS, n = 10, respectively). Mice in groups 2, 4, 6, 8, 10, and 12 were treated of a carcinogen, AOM (Sigma-Aldrich, St. Louis, MO, USA) by intraperitoneal injection at a concentration of 10 mg/kg at Day 0 in the experimental schedule ([Fig. 1A](#f1-jcp-21-271){ref-type="fig"}). For induction of colitis, 2.5 % (w/v) of DSS (MP Biomedicals, Aurora, OH, USA) was supplied in drinking water for seven days after one week from the injection of AOM.[@b17-jcp-21-271] Animals were euthanized by CO~2~ asphyxiation at 4, 10, and 16 weeks after the injection.

3. Macroscopic evaluation of tumor incidence and multiplicity
-------------------------------------------------------------

After the extracting the colons (from cecum to rectum), we opened them longitudinally and washed out the stools with PBS. Polypoid lesions under or above 2 mm in diameter were counted by three gastroenterologists in a blinded manner. Tumor multiplicity was defined as the number of gross polyps approved by the three gastroenterologists.

4. Histopathology
-----------------

The colonic segments containing any grossly proven polyps were fixed with phosphate-buffered formalin and were stained with hematoxylin and eosin (H&E). The classification of adenoma and adenocarcinoma was performed according to Hamilton and Aaltonen.[@b18-jcp-21-271] Additionally, the depth of invasion by adenocarcinoma in the colonic tissues was specified as mucosa and 'into the submucosa and muscularis'. The tumor incidence was evaluated as the percentage of rats with tumor.

5. Measurement of the level of cytokines
----------------------------------------

The amount of MPO and IL-1β in the colonic tissues was examined by ELISA using the appropriate kits (R&D systems, Minneapolis, MN, USA). Every assay was performed in triplicate.

6. Statistical analysis
-----------------------

Data were expressed as mean ± SEM. Statistical significance was examined with Mann-Whitney test or Fisher's exact test. *P* \< 0.05 was considered to indicate a statistical significance. All statistical analyses were conducted using PASW Statistics ver. 18.0 (IBM Co., Armonk, NY, USA) software.

RESULTS
=======

1. Incidence of colon adenoma and cancer induced with azoxymethane/dextran sulfate sodium
-----------------------------------------------------------------------------------------

The disease status of mouse colon was observed at week 2, 4, 10, and 16. In the macroscopic view, there were multiple polyps with big size in male colons while there were several small polyps in female colons ([Fig. 1B](#f1-jcp-21-271){ref-type="fig"}). To compare them in detail, the incidence and the multiplicity of tumors were evaluated macroscopically, and the tumors were classified by histological analysis ([Table 1](#t1-jcp-21-271){ref-type="table"}). At the fourth week, 50.0% (3/6) of male and 16.7% (1/6) of female mice had adenoma; and none of them had cancer. At the 10th week, the incidence rate of cancer in male was 70.0% (7/10) which was significantly different from that of the control group (*P* = 0.026). In female, adenoma occurred in 10.0% (1/10) and cancer appeared in 50.0% (5/10). There was no statistical significance in the change of each incidence rate (*P* = 1.000 for adenoma and 0.101 for cancer); however, the total incidence including adenoma and cancer was significantly increased (*P* = 0.044). At this time point, the submucosal invasion was observed in male. At the 16th week, the incidence rate was same in male and female; 60.0% (6/10) of male and female mice had cancer (*P* = 0.044). In both male and female mice, four out of six had mucosal invasion and two had submucosal invasion of tumor. However, at this time point, the tumor multiplicity of male was higher than female (8.30 ± 1.98 vs. 3.00 ± 0.54, *P* = 0.020). [Figure 1C](#f1-jcp-21-271){ref-type="fig"} shows the representative images of the incidence of tumor confirmed with histological analysis, displaying the time-dependent progression of adenoma and adenocarcinoma. In male, there was low grade adenoma at the fourth week, adenocarcinoma with focal submucosal invasion at the 10th week, and adenocarcinoma with submucosal invasion at the 16th week.

2. The tumor multiplicity differed according to the sex
-------------------------------------------------------

Since the tumor multiplicity at the 16th week was significantly different depending on the sex, it was analyzed in detail by the number of tumors under or above 2 mm in diameter. The number of small tumors with diameter under 2 mm was similar between male and female (*P* = 0.646) ([Fig. 2A](#f2-jcp-21-271){ref-type="fig"}); however, that of massive tumors of diameter above 2 mm was significantly higher in male than female (*P* = 0.026). According to the location of tumor, in male, tumors smaller than 2 mm in diameter were distributed more in the distal colon than the proximal colon (*P* = 0.035) ([Fig. 2B](#f2-jcp-21-271){ref-type="fig"}). The number of tumors larger than 2 mm in diameter was also relatively higher in male but there was no statistical significance (*P* = 0.099). Overall, in male, there were more tumors in distal colon (*P* = 0.001). In female, on the other hand, there was no significant difference in the distribution of tumors (*P* = 0.069 in smaller tumors, 0.615 in larger tumors than 2 mm in diameter, and 0.094 in total tumors).

3. Regulation of inflammatory cytokines
---------------------------------------

Increase of pro-inflammatory cytokine production is an important factor in the incidence of colorectal tumors. Therefore, following the evaluation of incidence of colon adenoma and cancer, we investigated on the expression of inflammatory cytokines in the colonic tissues. At the fourth week, the MPO was up-regulated in AOM/DSS-treated mice especially in female, which implies the activation of inflammation response (male, *P* = 0.086; female, *P* = 0.014) ([Fig. 3A](#f3-jcp-21-271){ref-type="fig"}). The level of IL-1β was also relatively higher in AOM/DSS group, but there was no statistical significance (male, *P* = 0.055; female, *P* = 0.144) ([Fig. 3B](#f3-jcp-21-271){ref-type="fig"}). At the 10th week, the IL-1β level of male control mice was significantly incremented compared to that of the fourth week (*P* = 0.016) while that of the female control mice remained similar (*P* = 0.917) ([Fig. 3B](#f3-jcp-21-271){ref-type="fig"}). Besides, the level of MPO was also relatively higher in male control with no statistical significance (*P* = 0.076) ([Fig. 3A](#f3-jcp-21-271){ref-type="fig"}). The reason of the increase of pro-inflammatory cytokines in control male mice has not been determined yet. At the 16th week, MPO was significantly increased compared to the fourth week (*P* = 0.027); and it was significantly higher in AOM/DSS-treated male mice compared to the control group (*P* = 0.003), whereas the corresponding female group showed no significant change (Comparison with the fourth week, *P* = 0.157; comparison with control group, *P* = 0.086) ([Fig. 3A](#f3-jcp-21-271){ref-type="fig"}). This implies that the up-regulation of MPO was more activated in male than in female. The IL-1β level significantly increased in male and female AOM/DSS groups compared to control groups at the 16th week (male, *P* = 0.014; female, *P* = 0.005) ([Fig. 3B](#f3-jcp-21-271){ref-type="fig"}). The level was relatively higher in male; however, there was no statistical significance (*P* = 0.226).

DISCUSSION
==========

In the present study, we observed that the time point of tumor incidence was earlier in male and that the total tumor number was significantly higher in male. According to the location, in male, the tumors were induced mostly in distal colon. At the same period, there was submucosal invasion in male. The pro-inflammatory cytokines (IL-1β and MPO) were up-regulated in both male and female mice due to AOM/DSS. In addition, IL-1β expression was also higher in male at 10th week in control.

Treating mice with AOM and DSS is a rapid and effective method for modeling human colitis-associated cancer. Using this model, the involvement of heritable factors can be studied by applying the AOM/DSS on genetically engineered mice.[@b19-jcp-21-271],[@b20-jcp-21-271] Also AOM/DSS model using wild-type mice can be applied in the research of the impact of pharmacologic target substances in colitis-associated cancer. However, little is known about the sex-associated discrepancies in this animal model. The current protocol reports that sex and age-matched mice may be used, the results using the female mice tended to be more consistent.[@b21-jcp-21-271],[@b22-jcp-21-271] As seen in this study, the biological response to the AOM and DSS was different depending on the sex, showing analogous aspects with the colon cancer in human.

The colitis-associated cancer is the cancer type preceded by the inflammatory bowel diseases (IBD).[@b6-jcp-21-271] Epidemiologically, the predominance of IBD in women is not generally appeared; it greatly differs according to the geographic regions.[@b23-jcp-21-271] In Asian populations, the IBD was rather consistently predominant in men;[@b24-jcp-21-271]--[@b27-jcp-21-271] on the other hand, in European and North-American populations, it ranged from equal distribution to female predominance.[@b28-jcp-21-271]--[@b36-jcp-21-271] Although the underlying mechanisms of gender differences in immune reactions are still unclear, the men are featured with more vulnerability to microbial infections, and women seems to be associated with autoimmunity.[@b37-jcp-21-271]--[@b39-jcp-21-271] The risk of colon cancer as the long-term complication was consistently higher in male IBD patients, according to a meta-analysis of population-based cohort studies.[@b40-jcp-21-271] Also the male IBD patients had increased mortality from colon cancer in a recently published meta-analysis.[@b41-jcp-21-271]

In human, there are sex-related biological differences in the colon cancer risk.[@b42-jcp-21-271] In a recent systemic review, it has been reported that a higher proportion of women were diagnosed with cancer in right-sided colon than men.[@b43-jcp-21-271] Also a major cohort study comparing the right-sided and left-sided colon cancer in 17,641 subjects also revealed the association of right-sided colon cancer and women.[@b44-jcp-21-271] In our results, the tumors located more in distal colon, which was consistent with the tendency in human.

The molecular characteristics of colon cancer exhibit discrepancies according to the tumor location, consequently depending on the sex. The left-sided colon cancer more frequently presents chromosomal instability which is related with 60% to 70% of colon cancer.[@b45-jcp-21-271]--[@b47-jcp-21-271] On the other hand, the right-sided colon cancer is associated with high MSI, CIMP, and *BRAF* mutation.[@b46-jcp-21-271],[@b47-jcp-21-271] The sex-related discrepancies in AOM/DSS model imply the possibility that the molecular features in murine colon may resemble that of humans.

Several evidences have reported the involvement of estrogen on the sex-associated differences in the colon cancer. A population-based case-control study (n = 4,246) suggested the protective impact of estrogen against MSI, and also reported that older women lacking estrogen had incremented risk of the colon cancer with high level of MSI.[@b48-jcp-21-271] The hormonal replacement therapy is known to decrease the risk of unstable tumors,[@b48-jcp-21-271] and also it was reported by the Women's Health Initiative Clinical Trial to reduce the risk of colon cancer by 40% in postmenopausal women.[@b49-jcp-21-271] Therefore, further investigations are suggested to study on the hormonal impacts by analyzing the effect of estrogen in male AOM/DSS model.

This study has several limitations. First, the measurement of pro-inflammatory factors was restricted to MPO and IL-1β. Investigations on the other cytokines are needed to figure out the mechanisms of the sex-related differences. Second, the distribution of tumor in female mice was incompletely analyzed because the tumor incidence was not sufficient at the end point (the 16th week). Long-term studies over 16 weeks may be helpful to confirm the tumor-incidence patterns according to locations in female mice.

Although the accumulating evidences have revealed the gender differences, the current screening guidelines for the colon cancer generally do not apply the gender-specific recommendations. The most commonly used colon cancer screening test, the fecal occult blood test is revealed to have different sensitivity by gender.[@b50-jcp-21-271] The diminished gender-specificity of the screening tools may be the reason of a higher mortality and shorter 5-year survival rate of women.

In conclusion, the inflammation-associated cancer was induced earlier and more severely in AOM/DSS-treated male than female mice by way of inflammatory mediators such as IL-1β and MPO. Thus, the sex-related differences at the animal model of colon cancer suggest the importance of approach to disease with sex-specific medicine in human.
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![Sex-associated differences in the colon adenoma and cancer induced with AOM/DSS. (A) Experimental protocol for the induction of colitis and colon cancer by AOM and DSS. (B) Representative macroscopic view of colons in each group sacrificed at week 16. (C) Representative histological images in 4th week (a) control male; AOM/DSS (b) male; (c) female. 10th week AOM/DSS (d) male; (e) female. 16th week AOM/DSS (f) male; (g) female. Occurrence of low grade adenoma in b; adenocarcinoma with focal submucosal invasion in d; high grade adenoma in e; adenocarcinoma with submucosal invasion in f; and adenocarcinoma in g (H&E; × 200 for a--c, × 100 for d and e, × 40 for f and g). Adenoma were indicated with dashed line circle; adenocarcinoma with full line circle; and submucosal invasion with arrows. M, male; F, female; AOM, azoxymethane; DSS, dextran sulfate sodium.](jcp-21-271f1){#f1-jcp-21-271}

![Tumor number according to (A) sex and (B) the colonic location. Data were expressed as mean ± SE. ^a^*P* \< 0.05 comparing distal and proximal; ^b^*P* \< 0.05 comparing male and female.](jcp-21-271f2){#f2-jcp-21-271}

![The levels of (A) myeloperoxidase (MPO) and (B) interleukin (IL)-1β in colonic mucosa measured with ELISA. Data were described as mean ± SE. ^a^*P* \< 0.05 comparing control and azoxymethane/dextran sulfate sodium (AOM/DSS); ^b^*P* \< 0.05 comparing male and female; ^c^*P* \< 0.05 compared to week 4; ^d^*P* \< 0.05 comparing week 10 and 16.](jcp-21-271f3){#f3-jcp-21-271}

###### 

Incidence and multiplicity of adenoma and cancer in colon

  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Group                                                  Adenoma incidence   Cancer incidence                                   Adenoma/cancer incidence                           Adenoma/cancer multiplicity                        Depth of invasion
  ------------------------------------------------------ ------------------- -------------------------------------------------- -------------------------------------------------- -------------------------------------------------- -------------------
  4-week male                                                                                                                                                                                                                         

   Control (n = 4)                                       0.0 (0/4)           0.0 (0/4)                                          0.0 (0/4)                                          0.0                                                

   AOM/DSS (n = 6)                                       50.0 (3/6)          0.0 (0/6)                                          50.0 (3/6)                                         0.67 ± 0.42                                        Mucosa (0)\
                                                                                                                                                                                                                                      Submucosa (0)

   *P*-value[a](#tfn2-jcp-21-271){ref-type="table-fn"}   0.200               1.000                                              1.000                                                                                                 

  4-week female                                                                                                                                                                                                                       

   Control (n = 5)                                       0.0 (0/5)           0.0 (0/5)                                          0.0 (0/5)                                          0.0                                                

   AOM/DSS (n = 6)                                       16.7 (1/6)          0.0 (0/6)                                          16.7 (1/6)                                         0.17 ± 0.17                                        Mucosa (0)\
                                                                                                                                                                                                                                      Submucosa (0)

   *P*-value[a](#tfn2-jcp-21-271){ref-type="table-fn"}   1.000               1.000                                              1.000                                                                                                 

   *P*-value[b](#tfn3-jcp-21-271){ref-type="table-fn"}                                                                                                                             0.138                                              

  10-week male                                                                                                                                                                                                                        

   Control (n = 5)                                       0.0 (0/5)           0.0 (0/5)                                          0.0 (0/5)                                          0.0                                                

   AOM/DSS (n = 10)                                      0.0 (0/10)          70.0 (7/10)                                        70.0 (7/10)                                        4.90 ± 0.87                                        Mucosa (6)\
                                                                                                                                                                                                                                      Submucosa (1)

   *P*-value[a](#tfn2-jcp-21-271){ref-type="table-fn"}   1.000               0.026[\*](#tfn4-jcp-21-271){ref-type="table-fn"}   0.026[\*](#tfn4-jcp-21-271){ref-type="table-fn"}                                                      

  10-week female                                                                                                                                                                                                                      

   Control (n = 5)                                       0.0 (0/5)           0.0 (0/5)                                          0.0 (0/5)                                          0.0                                                

   AOM/DSS (n = 10)                                      10.0 (1/10)         50.0 (5/10)                                        60.0 (6/10)                                        3.50 ± 1.40                                        Mucosa (5)\
                                                                                                                                                                                                                                      Submucosa (0)

   *P*-value[a](#tfn2-jcp-21-271){ref-type="table-fn"}   1.000               0.101                                              0.044[\*](#tfn4-jcp-21-271){ref-type="table-fn"}                                                      

   *P*-value[b](#tfn3-jcp-21-271){ref-type="table-fn"}                                                                                                                             0.235                                              

  16-week male                                                                                                                                                                                                                        

   Control (n = 5)                                       0.0 (0/5)           0.0 (0/5)                                          0.0 (0/5)                                          0.0                                                

   AOM/DSS (n = 10)                                      0.0 (0/10)          60.0 (6/10)                                        60.0 (6/10)                                        8.30 ± 1.98                                        Mucosa (4)\
                                                                                                                                                                                                                                      Submucosa (2)

   *P*-value[a](#tfn2-jcp-21-271){ref-type="table-fn"}   1.000               0.044[\*](#tfn4-jcp-21-271){ref-type="table-fn"}   0.044[\*](#tfn4-jcp-21-271){ref-type="table-fn"}                                                      

  16-week female                                                                                                                                                                                                                      

   Control (n = 5)                                       0.0 (0/5)           0.0 (0/5)                                          0.0 (0/5)                                          0.0                                                

   AOM/DSS (n = 10)                                      0.0 (0/10)          60.0 (6/10)                                        60.0 (6/10)                                        3.00 ± 0.54                                        Mucosa (4)\
                                                                                                                                                                                                                                      Submucosa (2)

   *P*-value[a](#tfn2-jcp-21-271){ref-type="table-fn"}   1.000               0.044[\*](#tfn4-jcp-21-271){ref-type="table-fn"}   0.044[\*](#tfn4-jcp-21-271){ref-type="table-fn"}                                                      

   *P*-value[b](#tfn3-jcp-21-271){ref-type="table-fn"}                                                                                                                             0.020[\*](#tfn4-jcp-21-271){ref-type="table-fn"}   
  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Values are presented as % (number/subtotal), mean ± SE, or (number) only. AOM, azoxymethane; DSS, dextran sulfate sodium.

Between control and AOM/DSS group. Fisher's exact test.

Between AOM/DSS male and female. Mann-Whitney test.

Asterisk means statistical significance (*P* \< 0.05).
